67 related articles for article (PubMed ID: 122622)
21. Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer.
Berendsen CL; Mulder TP; Peters WH
J Urol; 2000 Dec; 164(6):2126-8. PubMed ID: 11061940
[TBL] [Abstract][Full Text] [Related]
22. [The role of protein kinase C alpha in recurrence of superficial bladder carcinoma].
Zhu YY; Wang HM; Kong CZ; Liu DH; Li ZL; Sun ZX; Liu GF
Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):662-6. PubMed ID: 16008942
[TBL] [Abstract][Full Text] [Related]
23. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
24. Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer.
Witjes JA; Umbas R; Debruyne FM; Schalken JA
J Urol; 1995 Dec; 154(6):2185-9. PubMed ID: 7500486
[TBL] [Abstract][Full Text] [Related]
25. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
Mai KT; Yazdi HM; Farmer J
Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
[TBL] [Abstract][Full Text] [Related]
26. Sequential alkaline phosphatase changes in hyperplastic and neoplastic urothelium of mice fed 2-acetylaminofluorene.
Highman B; Frith CH; Littlefield NA
J Environ Pathol Toxicol; 1978; 1(3):223-31. PubMed ID: 722192
[No Abstract] [Full Text] [Related]
27. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder.
Swana HS; Smith SD; Perrotta PL; Saito N; Wheeler MA; Weiss RM
J Urol; 1999 Feb; 161(2):630-4. PubMed ID: 9915473
[TBL] [Abstract][Full Text] [Related]
28. [Ultrastructure of the basic cell types of human transitional cell bladder cancer].
Gaĭyrov AG
Arkh Patol; 1981; 43(6):46-52. PubMed ID: 7271498
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma.
Bénistant C; Chapuis H; Mottet N; Noletti J; Crapez E; Bali JP; Roche S
Biochem Biophys Res Commun; 2000 Jul; 273(2):425-30. PubMed ID: 10873622
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Li G; Yang T; Li L; Yan J; Zeng Y; Yu J; Zhang Y
Colloids Surf B Biointerfaces; 2004 Aug; 37(1-2):15-9. PubMed ID: 15450303
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 isoenzyme mRNA expression pattern in human urinary bladder malignancies and normal urothelium.
Brauers A; Manegold E; Buettner R; Baron JM; Merk HF; Jakse G
Cancer Detect Prev; 2000; 24(4):356-63. PubMed ID: 11059566
[TBL] [Abstract][Full Text] [Related]
32. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine.
Heine B; Hummel M; Müller M; Heicappell R; Miller K; Stein H
J Pathol; 1998 Jan; 184(1):71-6. PubMed ID: 9582530
[TBL] [Abstract][Full Text] [Related]
33. [The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues].
Ren L; Hou SK; He LF; Ye HY; Guan KP
Zhonghua Wai Ke Za Zhi; 2004 Sep; 42(18):1104-7. PubMed ID: 15498296
[TBL] [Abstract][Full Text] [Related]
34. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
35. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
Klein RD; Van Pelt CS; Sabichi AL; Dela Cerda J; Fischer SM; Fürstenberger G; Müller-Decker K
Cancer Res; 2005 Mar; 65(5):1808-13. PubMed ID: 15753378
[TBL] [Abstract][Full Text] [Related]
36. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
Dinney CP; Parker C; Dong Z; Fan D; Eve BY; Bucana C; Radinsky R
Clin Cancer Res; 1997 Feb; 3(2):161-8. PubMed ID: 9815668
[TBL] [Abstract][Full Text] [Related]
37. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas.
Varga A; Czifra G; Tállai B; Németh T; Kovács I; Kovács L; Bíró T
Eur Urol; 2004 Oct; 46(4):462-5. PubMed ID: 15363561
[TBL] [Abstract][Full Text] [Related]
38. Glutathione S-transferase-P1 expression correlates with increased antioxidant capacity in transitional cell carcinoma of the urinary bladder.
Savic-Radojevic A; Mimic-Oka J; Pljesa-Ercegovac M; Opacic M; Dragicevic D; Kravic T; Djokic M; Micic S; Simic T
Eur Urol; 2007 Aug; 52(2):470-7. PubMed ID: 17267100
[TBL] [Abstract][Full Text] [Related]
39. [Changes of urinary enzyme activity in cancer of the urinary bladder].
Nizamova RS
Vopr Onkol; 2006; 52(4):455-7. PubMed ID: 17024822
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia.
Visscher DW; Sloane BF; Sameni M; Babiarz JW; Jacobson J; Crissman JD
Mod Pathol; 1994 Jan; 7(1):76-81. PubMed ID: 8159656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
